Proof-of-concept radiolabeling studies were successfully performed synthesizing [165Er]PSMA-617, which will be utilized in vitro and in vivo to understand the role of AEs in PSMA-targeted radionuclide therapy of prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.